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Abstract
Background: Autosomal dominant non-autoimmune hyperthyroidism (ADNAH) is a rare genetic disorder of the endocrine
system. Molecular genetic studies in ADNAH have revealed heterozygous germline mutations in the TSHR. To data, mutations
leading to an increase in the constitutive activation of the TSHR have been described in the transmembrane segments,
exoloops and cytoplasmic loop of TSHR. These mutations result in constitutive activation of the Gas/cAMP or Gaq/11/inositol
phosphate (IP) pathways, which stimulate thyroid hormone production and thyroid proliferation.
Methodology/Principal Findings: In a previous study, we reported a new TSHR mutation located in the C-terminal domain
of TSHR, which results in a substitution of the conserved Ile
691 for Phe. In this study, to address the question of whether the
I691F mutated receptor could be responsible for Gas/cAMP or Gaq/11/IP constitutive activity, wild-type and TSHR mutants
were expressed in COS-7 cells to determine cAMP constitutive activity and IP formation. Compared to the cell surface with
expression of the A623V mutated receptor as positive control, the I691F mutated receptor showed a slight increase of cAMP
accumulation. Furthermore, I691F resulted in constitutive activation of the Gaq/11/IP signaling pathway.
Conclusions/Significance: Our results indicate that Ile
691 not only contributes to keeping TSHR inactive in the Gas/cAMP
pathways but also in the Gaq/11/IP cascade.
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Introduction
TSHR is a member of the superfamily of G-protein–coupled
transmembrane receptors mediating most of their intracellular actions
through G proteins [1]. The G protein family consists of the Gaand the
tightly associated Gbc subunits. There are four classes of Ga subunits:
Gas,G ai,G aq/11 and Ga12/13. Despite interaction of human TSHR
with all four Ga subunits, biological relevance has only been attributed
to the activation of Gas/cAMP, which is thought tor e g u l a t eg r o w t ha n d
differentiation of the thyroid; and to a lesser degree, to the activation of
Gaq/11/IP, which is thought to stimulate thyroid hormone synthesis and
iodination [2,3]. Familial non-autoimmune hyperthyroidism is an
autosomal dominant genetic disease resulting from mutations in the
TSHR. To data, mutations leading to an increase in the constitutive
activation of the TSHR have been described in the first, second, third,
fourth, fifth, sixth and seventh transmembrane segments, in the first,
second, third exoloops and in the second and third cytoplasmic loop
[4,5,6,7,8,9,10,11,12,13,14]. Some studies provided evidences that the
third intracellular loop plays a critical role in Gasprotein activation [15].
In particular, mutation of the conserved Ala
623 in third intracellular
loop was reported to result in loss of TSH-stimulated IP formation
l e a v i n gc A M Pa c c u m u l a t i o nu n a l t e r e d[ 1 6 ] .I ts u g g e s t st h a tt h eA l a
623
could be important for specific Gas protein coupling. Although it has
been shown that receptor/Gas protein interaction is determined by
specific amino acids, knowledge abou tt h ek e yp l a y e r si nt h i ss e l e c t i v e
interplay is still very limited.
In a previous study, we collected a Chinese family with ADNAH
across four generations. By mutation scan of the TSHR gene located
within the region of interest, a heterozygous substitution (ART) at
position 2071 of the TSHR was found, changing isoleucine 691 to
phenylalanine (Figure 1) [17]. In this study, using A623V as a positive
control, we utilized a combination of functional assays, site-directed
mutagenesis and image techniques to demonstrate that this mutation
causes constitutive activation of Gas/cAMP and Gaq/11/IP cascade
signaling, which suggests the key role of isoleucine at position 691 in
maintaining the inactive state between TSHR and Ga protein.
Results
Characterization of fluorescent proteins of wild-type and
TSHR mutants
By fusing GFP fluorescent reporters to the TSHR, we generated
fluorescent chimeras of GFP-TSHR, GFP-TSHR (I691F) and
GFP-TSHR (A623V) mutants to investigate their subcellular
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16335localizations by fluorescence microscopy. Wild-type TSHR
chimeras were clearly expressed at the cell membrane. In contrast,
I691F and A623V mutants’ chimeras were retained in cytoplasm
and poorly expressed on the plasma membrane (Figure 2A). To
exclude the possibility that the intracellular retention of mutant
receptors could be simply due to higher expression levels, a
Western blot analysis was performed. The result shows that the
total level of protein expression is similar for all constructs
(Figure 2B).
Cell surface expression
The level of receptor expression on the cell surface for the
different constructs was independently measured by flow cytom-
etry. Fluorescence intensity is expressed in arbitrary units as a
function of cell number plotted on a logarithmic scale (Figure 3A).
These two mutations led to a marked decrease expression of the
mutated receptors on the cell surface compared to the wild-type
TSHR (set at 100%), 74.6% for A623V and 86.4% for I691F
respectively (Table 1, Figure 3B). The pEGFP-N1vector is not
present on the cell membrane.
Basal and TSH-stimulated cAMP production
Cells transfected with the I691F exhibited a 4 fold increase in
basal cAMP accumulation with respect to cells transfected with
wild-type TSHR, showing a constitutive activation (Table 1,
Figure 4). Cells transfected with the mutants A623V displayed
higher level (6 fold) of basal cAMP compared to the wild-type
TSHR (set at 1). Furthermore, the biological response to bTSH of
the cells transfected with the DNA of the mutated constructs was
explored in terms of cAMP accumulation. I691F was able to
produce a significant cAMP stimulation of 12 fold after 100 mU/
ml of bTSH stimulation, which was lower than 16 fold that
produced by A623V compared with the wild-type TSHR (set at 1)
(Table 1, Figure 4).
Basal and TSH-stimulated inositol phosphate formation
As expected from previous studies, no significant increase of
basal levels of IP production was observed in the cells transfected
with A623V [16]. However, an increase was observed in cells
transfected with the wild-type TSHR and I691F, showing a
constitutive activity for the IP production. Cells transfected with
the I691F mutant showed a slight increase of 3 fold in basal IP
production with respect to wild-type TSHR (set at 1) (Table 1,
Figure 5). Furthermore, stimulation of IP accumulation by
100 mU/ml of bTSH, I691F showed a significant increased
production (8 fold) of IP with respect to the wild-type TSHR (set at
1) (Table 1, Figure 5).
Discussion
Our finding supports the idea that the cytoplasmic tail region is
a potential interaction site between TSHR and Gas protein. The
difference in basal cAMP level reflects the ability of the mutant
receptors to activate the Gas/cAMP pathway [18]. The A623V
construct had 1–2 fold higher levels in cAMP response than I691F.
So, A623V mutation exhibited stronger constitutive activity,
indicating that A623V critically required for productive Gas
coupling. Moreover, these results support the hypothesis that there
are several active conformations of the TSHR, which differ in
their capability to activate different downstream signaling
cascades, as previously reported [19,20,21]. The vast majority of
TSHR mutations activate the Gas/cAMP system, but only a few
TSH receptor mutations can also activate the Gaq/11/IP pathway,
Figure 1. Schematic representation of the TSHR mutants (A623V and I691F). The mutants with A623V and I691F desciribed in this article.
A623V and I691F locte in third intracellular loop and cytoplasmic tail region of TSHR respectively.
doi:10.1371/journal.pone.0016335.g001
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ADNAH remain unknown [22,23]. In previous studies, the
substitution of Ala
623 with different amino acids lead to
constitutive activation of the Gas/cAMP cascade and to a selective
loss of Gaq/11/IP signaling of the TSHR [16]. Our research also
showed that A623V had full cAMP responses, but blunted IP
responses. Interestingly, our work demonstrated I691F could
active both Gas/cAMP and Gaq/11/IP signaling pathways. These
findings suggest that (1) Ile
691 belongs to the cytoplasmic tail
proposed to play a role in Gaq/11/IP signal transduction; and (2)
Ile
691 is responsible for the maintenance of TSHR in the inactive
state.
Chazenbalk et al. showed that residues 709–764, two-thirds of
the C-terminal domain of the cytoplasmic tail, can be removed
without functional impairment of the TSHR suggesting that the
cytoplasmic tail may play a nonessential role [24,25]. However,
other reports showed the half of the cytoplasmic tail (up to residue
721) is essential for full expression of functional activities [26].
Sequence comparison revealed that the C-terminal amino acids
within 698–695 are highly conserved within the family of TSHR
(Figure 6). In general, the substitution of isoleucine for phenylal-
anine would be considered as a ‘safe’ residue substitution in a
protein because the change from isoleucine to phenylalanine
represents a conservative substitution as both are nonpolar,
hydrophobic amino acids [27]. However, phenylalanine is
considerably bulkier as it has a benzene ring. This maybe disrupts
the tight association of the amino acids and impairs folding and
trafficking of the mutated receptors leading to constitutive activity
of signaling pathways. Moreover, this molecular change may
provide in the transformed cells a very strong signal, resulting not
only in the growth advantage by stimulation of Gas/cAMP
pathways, but also activation by Gaq/11/IP pathways. This may
eventually explain why the ‘safe’ mutation I691F causes ADNAH.
In conclusion, we identified a new mutation with the ability to
constitutively activate both Gas/cAMP and Gaq/11/IP pathways in
the cytoplasmic tail region of the human TSHR. Although the role
of cytoplasmic tail region of TSHR is not known very well, our
data support the concepts that the cytoplasmic tail play a role in
signal transduction and that Ile
691 contributes in keeping TSHR
inactive in both the Gas/cAMP and the Gaq/11/IP pathways. Our
finding could give a new insight into the molecular mechanisms of
TSHR activation.
Materials and Methods
Generation of TSHR mutants
cDNA encoding the human TSHR was obtained by RT-PCR
as described by Alberti [5]. In brief, genomic DNA was extracted
from peripheral blood by DNA Extraction Kit (TaKaRa)
according to the manufacturer’s instructions. The RT-PCR was
performed using the following primers, forward: 59-GAG GAT
GGA GAA ATA GCC CCG AG-39 and reverse: 59-GTG TCA
TGG GAT TGG AAT-39 [14], and then cloned into the
eukaryotic expression vector pEGFP-N1 (Clontech) to generate
the pEGFP-N1-TSHR. Mutation I691F and A623V were created
by site-directed mutagenesis using QuikChange Site-Directed
Mutagenesis kit (Stratagene) according to the manufacturer’s
instructions using expression plasmid pEGFP-N1-TSHR as a
Figure 2. Characterization of chimeric constructs of TSHR and fluorescent reporters. (A) COS-7 cells transfected with GFP chimeras of wild-
type or TSHR mutants and visualized by fluorescence microscopy. Wild-type TSH receptor is expressed at the plasma membrane. Mutant A623V and
I691F receptors are poorly expressed at the plasma membrane and are retained in intracellular regions; and (B) Western blot analysis of different GFP
chimeras using an anti-human TSHR antibody (H-115) antibody. The band consistent with the molecular weights of receptor (,90 kDa, TSHR + GFP)
forms were present.
doi:10.1371/journal.pone.0016335.g002
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generated by primers 59- GAT ACC AAA ATT GTC AAG AGG ATG
GCT- 39,5 9-A G CC A TC C TC T TG A CA A TT T TG G TA T C-
39and 59- AGG GAT GTG TTC TTC CTA CTC AGC AAG - 39,5 9-
CTT GCT GAG TAG GAA GAA CAC ATC CCT - 39 respectively.
The PCR products were sequenced by ABI 3100 automatic sequencer.
Cell culture and transient expression of TSHR mutants
COS-7 cells were maintained in Dulbecco’s Modified Eagle
Medium containing 10% fetal bovine serum and 100 mg/ml
penicillin-streptomycin (Invitrogen) in a humidified atmosphere of
5% CO2 in air at 37uC. COS-7 cells were seeded into wells of 6-
well dishes overnight and transfected with 250 ng of plasmid using
Lipofectamine 2000 (Invitrogen), according to manufacturer’s
instructions. One day before transfection, 2–5610
5 cells were
plated in 2 ml of growth medium without antibiotics, so that cells
will be 80–90% confluent at the time of transfection. Cells
transfected with the pEGFP-N1 vector were used as controls.
Total protein extraction and Western blot analysis
The COS-7 cells were harvested 48 hours after transfection and
then lysed for 1 hour on ice with lysis buffer to extract protein. In
Figure 3. Cell surface expression determined by Flow cytometry analysis. (A) COS-7 cells were assayed after transfection with pEGFP-N1-
vector, wild-type TSHR, mutants A623V and I691F. Fluorescence intensity is expressed in arbitrary units as a function of cell number plotted on a
logarithmic scale. Representative mutants are shown. (B) Expression level of the pEGFP-N1, wild-type TSHR and mutants with A623V and I691F. Data
are expressed as percentage expression of wild-type TSHR (set at 100%) and are presented as means 6 S.E.M. of three independent experiments,
each carried out in duplicate. *p,0.05; **p,0.001.
doi:10.1371/journal.pone.0016335.g003
Table 1. Functional characterization of TSHR mutants.
Transfected
constructs
Cell surface
Expression (% of
wild-type TSHR) cAMP accumulation (Fold over wild-type TSHR basal) IP accumulation (Fold over wild-type TSHR basal)
0 mU/ml bTSH
Basal
10 mU/ml
bTSH
100 mU/ml
bTSH
0 mU/ml bTSH
Basal
10 mU/ml
bTSH
100 mU/ml
bTSH
wild-type TSHR 100 1 3.261.12 8.261.27 1 2.260.7 6.160.12
A623V 74.664.9 5.860.3 9.661.2 16.361.4 0.360.04 0.760.02 0.960.1
I691F 86.465.2 3.960.08 6.460.19 12.161.1 2.760.2 7.361.1 8.261.9
pEGFP-N1 3.860.7 0.360.04 02.60.02 0.460.06 0.260.01 0.360.03 0.360.01
doi:10.1371/journal.pone.0016335.t001
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with pEGFP-N1-vector, wild-type TSHR and mutants with A623V and I691F. Forty-eight hours after transfection, COS-7 cells were incubated in 10 or
100 mU/ml bTSH. cAMP levels were determined as described in materials and methods. Data are expressed as relative to wild-type basal and given as
means 6 S.E.M. of three independent experiments, each carried out in triplicate. *p,0.05; **p,0.001.
doi:10.1371/journal.pone.0016335.g004
Figure 5. Basal and TSH-stimulated IP accumulation. COS-7 cells were transfeted with pEGFP-N1-vector, wild-type TSHR and mutants with
A623V and I691F. Twenty-fourt hours after transfection, cells were incubated in 10 or 100 mU/ml bTSH. IP accumulation was determined as described
in materials and methods. The basal IP production of the wild-type TSHR was set at 1 and all other data are expressed as fold of the basal IP
production of the wild-type TSHR. Data are presented as means 6 S.E.M. of two independent experiments, each carried out in triplicate. *p,0.05;
**p,0.001.
doi:10.1371/journal.pone.0016335.g005
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amide gels. Rainbow prestained molecular mass markers (Invitro-
gen) were used as the standard. After electrophoresis, the
separated proteins were transferred to a 0.45 mm nitrocellulose
membrane. The membranes were blocked with 5% fat-free milk in
PBS buffer for 1 hour at room temperature. After being washed
three times with PBS containing 0.1% Triton X-100, the
membranes were incubated with mouse anti-human TSHR
antibody (H-115) 1:2000 or anti-Actin (C-2) 1:3000 (Santa Cruz
Biotech) in PBS with 0.1% BSA at 4uC overnight. The membranes
were washed four times with PBS before hybridizing with
secondary antibody. Signals were developed by using Amersham
ECL
TM Western Blotting System (GE Healthcare).
Flow cytometry
The TSH receptor cell surface expression level was quantified
on a FACS flow cytometer. Transfected cells were washed twice
with PBS and transferred into Falcon tubes. Cells were washed
once with PBS containing 0.1% BSA and then incubated at 4uC
for 1 hour with a 1:400 dilution of a rabbit anti-human TSHR
antibody (H-115). After rinse, the cells were washed twice with
PBS and incubated at 4uC for 1 hour with a 1:200 fluorescein-
FITC mouse anti- rabbit IgG (2A9) (Santa Cruz Biotech). Before
FACS analysis (FACscan, BD Biosciences), cells were washed
twice and then fixed with 1% paraformaldehyde. The level of
wild-type TSHR was set as 100% and receptor expression of the
mutants was calculated according to the level of wild-type TSHR.
Cell-cycle data was analyzed using the ModFIT software version
3.0 (Verity Software House, ME).
cAMP accumulation assay
To determine cAMP, the culture medium was removed
48 hours after transfection. Thereafter, cells were incubated at
37uC for 60 min in fresh Krebs-Ringer-HEPES buffer, 0.5% BSA
and the indicated concentrations of bovine (b) TSH (Sigma). The
medium was removed and the reaction was stopped by adding
0.1 M HCl. Supernatants were collected, dried, resuspended in
water, and then diluted appropriately for cAMP measurements.
cAMP content of the cell extracts was determined using the cAMP
Parameter Assay Kit (R&D Systems) according to the manufac-
turer’s instructions.
Inositol phosphate assay
To measure IP, transfected COS-7 cells in 6-well culture plates
(2610
5/well) were allowed to grow for 24 hours. Thereafter, cells
were washed three times with serum-free DMEM without
antibiotics. After being washed with PBS, cells were incubated
for 30 min in 10 mM LiCl at 37uC and then were exposed for
15 min to various concentrations of bTSH. The reactions were
terminated by addition of ice-cold perchloric acid to a final
concentration of 2.5%. The samples were centrifuged at 20006g
for 15 min at 4uC to remove perchloric acid precipitate. TSH-
induced increases in intracellular IP levels were determined by D-
myo-Inositol 1, 4, 5-trisphosphate (IP3)[
3H] assay system (GE
Healthcare).
Statistical analysis
The one-way analysis of variance (ANOVA) was used for group
comparisons of different treatments. Adjustment for multiple
pairwise comparisons was accomplished using the adaptation of
the Tukey method in conjunction with an overall 0.05 level of
significance. The results were reported after adjustment for
multiple comparisons. All analyses were implemented using SPSS
13.0 for Windows.
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